nodes	percent_of_prediction	percent_of_DWPC	metapath
Lenalidomide—PTGS2—urinary bladder cancer	0.369	1	CbGaD
Lenalidomide—ABCB1—Mitomycin—urinary bladder cancer	0.0886	0.309	CbGbCtD
Lenalidomide—PTGS2—Cisplatin—urinary bladder cancer	0.0561	0.196	CbGbCtD
Lenalidomide—PTGS2—Etoposide—urinary bladder cancer	0.0552	0.193	CbGbCtD
Lenalidomide—ABCB1—Gemcitabine—urinary bladder cancer	0.0255	0.089	CbGbCtD
Lenalidomide—ABCB1—Cisplatin—urinary bladder cancer	0.0185	0.0646	CbGbCtD
Lenalidomide—ABCB1—Etoposide—urinary bladder cancer	0.0182	0.0635	CbGbCtD
Lenalidomide—ABCB1—Doxorubicin—urinary bladder cancer	0.0124	0.0433	CbGbCtD
Lenalidomide—ABCB1—Methotrexate—urinary bladder cancer	0.012	0.042	CbGbCtD
Lenalidomide—CDH5—prostate gland—urinary bladder cancer	0.00714	0.0977	CbGeAlD
Lenalidomide—CDH5—seminal vesicle—urinary bladder cancer	0.00604	0.0826	CbGeAlD
Lenalidomide—CDH5—epithelium—urinary bladder cancer	0.00525	0.0718	CbGeAlD
Lenalidomide—CDH5—smooth muscle tissue—urinary bladder cancer	0.00506	0.0692	CbGeAlD
Lenalidomide—CDH5—urethra—urinary bladder cancer	0.00478	0.0654	CbGeAlD
Lenalidomide—CRBN—prostate gland—urinary bladder cancer	0.00454	0.062	CbGeAlD
Lenalidomide—CDH5—female reproductive system—urinary bladder cancer	0.0039	0.0533	CbGeAlD
Lenalidomide—CRBN—seminal vesicle—urinary bladder cancer	0.00384	0.0525	CbGeAlD
Lenalidomide—CDH5—vagina—urinary bladder cancer	0.00353	0.0482	CbGeAlD
Lenalidomide—CRBN—renal system—urinary bladder cancer	0.00309	0.0423	CbGeAlD
Lenalidomide—CRBN—urethra—urinary bladder cancer	0.00304	0.0415	CbGeAlD
Lenalidomide—TNFSF11—lymph node—urinary bladder cancer	0.00303	0.0415	CbGeAlD
Lenalidomide—CRBN—female reproductive system—urinary bladder cancer	0.00248	0.0339	CbGeAlD
Lenalidomide—Pomalidomide—TNF—urinary bladder cancer	0.00242	0.412	CrCbGaD
Lenalidomide—CDH5—lymph node—urinary bladder cancer	0.00228	0.0312	CbGeAlD
Lenalidomide—CRBN—vagina—urinary bladder cancer	0.00224	0.0306	CbGeAlD
Lenalidomide—Thalidomide—TNF—urinary bladder cancer	0.00156	0.266	CrCbGaD
Lenalidomide—CRBN—lymph node—urinary bladder cancer	0.00145	0.0198	CbGeAlD
Lenalidomide—PTGS2—prostate gland—urinary bladder cancer	0.00124	0.0169	CbGeAlD
Lenalidomide—Pomalidomide—PTGS2—urinary bladder cancer	0.00115	0.196	CrCbGaD
Lenalidomide—PTGS2—seminal vesicle—urinary bladder cancer	0.00104	0.0143	CbGeAlD
Lenalidomide—PTGS2—epithelium—urinary bladder cancer	0.000908	0.0124	CbGeAlD
Lenalidomide—PTGS2—smooth muscle tissue—urinary bladder cancer	0.000875	0.012	CbGeAlD
Lenalidomide—PTGS2—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—HPGDS—urinary bladder cancer	0.000867	0.0232	CbGpPWpGaD
Lenalidomide—CDH5—Cell-cell junction organization—CDH1—urinary bladder cancer	0.000847	0.0227	CbGpPWpGaD
Lenalidomide—PTGS2—renal system—urinary bladder cancer	0.000842	0.0115	CbGeAlD
Lenalidomide—PTGS2—urethra—urinary bladder cancer	0.000827	0.0113	CbGeAlD
Lenalidomide—TNFSF11—IL6-mediated signaling events—MYC—urinary bladder cancer	0.000812	0.0218	CbGpPWpGaD
Lenalidomide—TNFSF11—RANKL/RANK Signaling Pathway—SRC—urinary bladder cancer	0.000799	0.0214	CbGpPWpGaD
Lenalidomide—ABCB1—prostate gland—urinary bladder cancer	0.000764	0.0104	CbGeAlD
Lenalidomide—Thalidomide—PTGS2—urinary bladder cancer	0.000739	0.126	CrCbGaD
Lenalidomide—CDH5—Signaling events mediated by VEGFR1 and VEGFR2—RHOA—urinary bladder cancer	0.000698	0.0187	CbGpPWpGaD
Lenalidomide—PTGS2—female reproductive system—urinary bladder cancer	0.000674	0.00922	CbGeAlD
Lenalidomide—ABCB1—seminal vesicle—urinary bladder cancer	0.000646	0.00884	CbGeAlD
Lenalidomide—CDH5—Cell junction organization—CDH1—urinary bladder cancer	0.000641	0.0172	CbGpPWpGaD
Lenalidomide—PTGS2—vagina—urinary bladder cancer	0.00061	0.00834	CbGeAlD
Lenalidomide—PTGS2—Arachidonic acid metabolism—CYP4B1—urinary bladder cancer	0.000589	0.0158	CbGpPWpGaD
Lenalidomide—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP4B1—urinary bladder cancer	0.000568	0.0152	CbGpPWpGaD
Lenalidomide—ABCB1—epithelium—urinary bladder cancer	0.000561	0.00768	CbGeAlD
Lenalidomide—ABCB1—renal system—urinary bladder cancer	0.000521	0.00712	CbGeAlD
Lenalidomide—ABCB1—urethra—urinary bladder cancer	0.000512	0.007	CbGeAlD
Lenalidomide—CDH5—Signaling events mediated by VEGFR1 and VEGFR2—SRC—urinary bladder cancer	0.000511	0.0137	CbGpPWpGaD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—RHOA—urinary bladder cancer	0.000486	0.013	CbGpPWpGaD
Lenalidomide—PTGS2—C-MYB transcription factor network—PTCRA—urinary bladder cancer	0.000472	0.0127	CbGpPWpGaD
Lenalidomide—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—GSTO2—urinary bladder cancer	0.000459	0.0123	CbGpPWpGaD
Lenalidomide—CDH5—Signaling by VEGF—RHOA—urinary bladder cancer	0.000459	0.0123	CbGpPWpGaD
Lenalidomide—CDH5—Cell-Cell communication—CDH1—urinary bladder cancer	0.000456	0.0122	CbGpPWpGaD
Lenalidomide—ABCB1—female reproductive system—urinary bladder cancer	0.000417	0.0057	CbGeAlD
Lenalidomide—PTGS2—lymph node—urinary bladder cancer	0.000394	0.00539	CbGeAlD
Lenalidomide—ABCB1—vagina—urinary bladder cancer	0.000377	0.00516	CbGeAlD
Lenalidomide—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—SLC19A1—urinary bladder cancer	0.000357	0.00957	CbGpPWpGaD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—SRC—urinary bladder cancer	0.000356	0.00954	CbGpPWpGaD
Lenalidomide—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—PRSS3—urinary bladder cancer	0.000348	0.00932	CbGpPWpGaD
Lenalidomide—CDH5—Signaling by VEGF—SRC—urinary bladder cancer	0.000336	0.009	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—HPGDS—urinary bladder cancer	0.000335	0.00897	CbGpPWpGaD
Lenalidomide—PTGS2—Arachidonic acid metabolism—HPGDS—urinary bladder cancer	0.000313	0.00839	CbGpPWpGaD
Lenalidomide—CDH5—Cell-Cell communication—SRC—urinary bladder cancer	0.000304	0.00816	CbGpPWpGaD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—KRAS—urinary bladder cancer	0.000295	0.0079	CbGpPWpGaD
Lenalidomide—ABCB1—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	0.000291	0.00781	CbGpPWpGaD
Lenalidomide—CDH5—Signaling by VEGF—KRAS—urinary bladder cancer	0.000278	0.00745	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—NQO1—urinary bladder cancer	0.00027	0.00723	CbGpPWpGaD
Lenalidomide—PTGS2—S1P1 pathway—RHOA—urinary bladder cancer	0.000261	0.007	CbGpPWpGaD
Lenalidomide—CDH5—VEGFA-VEGFR2 Pathway—HRAS—urinary bladder cancer	0.00025	0.00671	CbGpPWpGaD
Lenalidomide—ABCB1—lymph node—urinary bladder cancer	0.000244	0.00334	CbGeAlD
Lenalidomide—PTGS2—C-MYB transcription factor network—BIRC3—urinary bladder cancer	0.000239	0.0064	CbGpPWpGaD
Lenalidomide—CDH5—Signaling by VEGF—HRAS—urinary bladder cancer	0.000236	0.00633	CbGpPWpGaD
Lenalidomide—PTGS2—Overview of nanoparticle effects—CXCL8—urinary bladder cancer	0.000229	0.00615	CbGpPWpGaD
Lenalidomide—PTGS2—C-MYB transcription factor network—MPO—urinary bladder cancer	0.000204	0.00547	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—HDAC4—urinary bladder cancer	0.000204	0.00547	CbGpPWpGaD
Lenalidomide—PTGS2—Signaling mediated by p38-alpha and p38-beta—ESR1—urinary bladder cancer	0.000202	0.00542	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—MPO—urinary bladder cancer	0.000197	0.00527	CbGpPWpGaD
Lenalidomide—PTGS2—Arachidonic acid metabolism—GPX1—urinary bladder cancer	0.000185	0.00497	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—GLI1—urinary bladder cancer	0.000171	0.00458	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—ESR1—urinary bladder cancer	0.000162	0.00435	CbGpPWpGaD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—TFRC—urinary bladder cancer	0.000162	0.00433	CbGpPWpGaD
Lenalidomide—PTGS2—Overview of nanoparticle effects—TNF—urinary bladder cancer	0.00016	0.00428	CbGpPWpGaD
Lenalidomide—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL2—urinary bladder cancer	0.000156	0.00419	CbGpPWpGaD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CDK4—urinary bladder cancer	0.000153	0.00409	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—RB1—urinary bladder cancer	0.000142	0.0038	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—LIG1—urinary bladder cancer	0.000141	0.00377	CbGpPWpGaD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—PPARG—urinary bladder cancer	0.000139	0.00372	CbGpPWpGaD
Lenalidomide—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000134	0.00359	CbGpPWpGaD
Lenalidomide—PTGS2—C-MYB transcription factor network—GSTM1—urinary bladder cancer	0.000128	0.00342	CbGpPWpGaD
Lenalidomide—PTGS2—C-MYB transcription factor network—NCOR1—urinary bladder cancer	0.000128	0.00342	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—SOD2—urinary bladder cancer	0.000124	0.00331	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—GPX1—urinary bladder cancer	0.000118	0.00316	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—RBX1—urinary bladder cancer	0.000117	0.00314	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—TSC1—urinary bladder cancer	0.00011	0.00295	CbGpPWpGaD
Lenalidomide—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—MTHFR—urinary bladder cancer	0.00011	0.00294	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—MTHFR—urinary bladder cancer	0.000109	0.00292	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—HPGDS—urinary bladder cancer	0.000107	0.00287	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—IGFBP3—urinary bladder cancer	0.000106	0.00285	CbGpPWpGaD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CXCL8—urinary bladder cancer	0.000106	0.00284	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—JAG1—urinary bladder cancer	0.000105	0.00281	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—CDKN1A—urinary bladder cancer	0.000102	0.00273	CbGpPWpGaD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—urinary bladder cancer	0.000101	0.00271	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—LIG1—urinary bladder cancer	9.96e-05	0.00267	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—EP300—urinary bladder cancer	9.69e-05	0.0026	CbGpPWpGaD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—TERT—urinary bladder cancer	9.68e-05	0.00259	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—SRC—urinary bladder cancer	9.43e-05	0.00253	CbGpPWpGaD
Lenalidomide—PTGS2—C-MYB transcription factor network—CREBBP—urinary bladder cancer	8.79e-05	0.00236	CbGpPWpGaD
Lenalidomide—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—urinary bladder cancer	8.63e-05	0.00231	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—ESR2—urinary bladder cancer	8.57e-05	0.0023	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—FAS—urinary bladder cancer	8.52e-05	0.00229	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—S100B—urinary bladder cancer	8.49e-05	0.00228	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—MYC—urinary bladder cancer	8.45e-05	0.00226	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	8.41e-05	0.00226	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—EGFR—urinary bladder cancer	8.26e-05	0.00222	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—TNF—urinary bladder cancer	7.87e-05	0.00211	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—KRAS—urinary bladder cancer	7.81e-05	0.00209	CbGpPWpGaD
Lenalidomide—PTGS2—C-MYB transcription factor network—CDKN2A—urinary bladder cancer	7.7e-05	0.00206	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—CDK4—urinary bladder cancer	7.68e-05	0.00206	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—NCOR1—urinary bladder cancer	7.63e-05	0.00205	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—HPGDS—urinary bladder cancer	7.6e-05	0.00204	CbGpPWpGaD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—CREBBP—urinary bladder cancer	7.56e-05	0.00203	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—IGFBP3—urinary bladder cancer	7.55e-05	0.00202	CbGpPWpGaD
Lenalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—urinary bladder cancer	7.36e-05	0.00197	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	6.89e-05	0.00185	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CCNE1—urinary bladder cancer	6.82e-05	0.00183	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—TERT—urinary bladder cancer	6.73e-05	0.0018	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TYMS—urinary bladder cancer	6.7e-05	0.0018	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—RB1—urinary bladder cancer	6.67e-05	0.00179	CbGpPWpGaD
Lenalidomide—PTGS2—Aryl Hydrocarbon Receptor—HRAS—urinary bladder cancer	6.64e-05	0.00178	CbGpPWpGaD
Lenalidomide—PTGS2—C-MYB transcription factor network—CCND1—urinary bladder cancer	6.51e-05	0.00174	CbGpPWpGaD
Lenalidomide—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	6.4e-05	0.000281	CcSEcCtD
Lenalidomide—Epistaxis—Doxorubicin—urinary bladder cancer	6.38e-05	0.00028	CcSEcCtD
Lenalidomide—Angiopathy—Methotrexate—urinary bladder cancer	6.37e-05	0.000279	CcSEcCtD
Lenalidomide—Sinusitis—Doxorubicin—urinary bladder cancer	6.35e-05	0.000279	CcSEcCtD
Lenalidomide—Immune system disorder—Methotrexate—urinary bladder cancer	6.34e-05	0.000278	CcSEcCtD
Lenalidomide—Dizziness—Fluorouracil—urinary bladder cancer	6.34e-05	0.000278	CcSEcCtD
Lenalidomide—Visual impairment—Epirubicin—urinary bladder cancer	6.33e-05	0.000278	CcSEcCtD
Lenalidomide—Mediastinal disorder—Methotrexate—urinary bladder cancer	6.32e-05	0.000277	CcSEcCtD
Lenalidomide—Agranulocytosis—Doxorubicin—urinary bladder cancer	6.32e-05	0.000277	CcSEcCtD
Lenalidomide—Chills—Methotrexate—urinary bladder cancer	6.3e-05	0.000276	CcSEcCtD
Lenalidomide—PTGS2—C-MYB transcription factor network—CDKN1A—urinary bladder cancer	6.29e-05	0.00169	CbGpPWpGaD
Lenalidomide—Diarrhoea—Cisplatin—urinary bladder cancer	6.22e-05	0.000273	CcSEcCtD
Lenalidomide—Erythema multiforme—Epirubicin—urinary bladder cancer	6.21e-05	0.000272	CcSEcCtD
Lenalidomide—Alopecia—Methotrexate—urinary bladder cancer	6.2e-05	0.000272	CcSEcCtD
Lenalidomide—Vomiting—Gemcitabine—urinary bladder cancer	6.2e-05	0.000272	CcSEcCtD
Lenalidomide—Bradycardia—Doxorubicin—urinary bladder cancer	6.19e-05	0.000271	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—FGFR3—urinary bladder cancer	6.17e-05	0.00165	CbGpPWpGaD
Lenalidomide—Mental disorder—Methotrexate—urinary bladder cancer	6.15e-05	0.00027	CcSEcCtD
Lenalidomide—Rash—Gemcitabine—urinary bladder cancer	6.15e-05	0.00027	CcSEcCtD
Lenalidomide—Dermatitis—Gemcitabine—urinary bladder cancer	6.14e-05	0.000269	CcSEcCtD
Lenalidomide—Eye disorder—Epirubicin—urinary bladder cancer	6.14e-05	0.000269	CcSEcCtD
Lenalidomide—Hypersensitivity—Etoposide—urinary bladder cancer	6.13e-05	0.000269	CcSEcCtD
Lenalidomide—Tinnitus—Epirubicin—urinary bladder cancer	6.12e-05	0.000269	CcSEcCtD
Lenalidomide—Malnutrition—Methotrexate—urinary bladder cancer	6.11e-05	0.000268	CcSEcCtD
Lenalidomide—Erythema—Methotrexate—urinary bladder cancer	6.11e-05	0.000268	CcSEcCtD
Lenalidomide—Haemoglobin—Doxorubicin—urinary bladder cancer	6.11e-05	0.000268	CcSEcCtD
Lenalidomide—Headache—Gemcitabine—urinary bladder cancer	6.11e-05	0.000268	CcSEcCtD
Lenalidomide—Flushing—Epirubicin—urinary bladder cancer	6.09e-05	0.000267	CcSEcCtD
Lenalidomide—Cardiac disorder—Epirubicin—urinary bladder cancer	6.09e-05	0.000267	CcSEcCtD
Lenalidomide—Vomiting—Fluorouracil—urinary bladder cancer	6.09e-05	0.000267	CcSEcCtD
Lenalidomide—Rhinitis—Doxorubicin—urinary bladder cancer	6.09e-05	0.000267	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—ESR2—urinary bladder cancer	6.08e-05	0.00163	CbGpPWpGaD
Lenalidomide—Haemorrhage—Doxorubicin—urinary bladder cancer	6.08e-05	0.000267	CcSEcCtD
Lenalidomide—Hepatitis—Doxorubicin—urinary bladder cancer	6.08e-05	0.000267	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—RHOA—urinary bladder cancer	6.06e-05	0.00162	CbGpPWpGaD
Lenalidomide—Hypoaesthesia—Doxorubicin—urinary bladder cancer	6.05e-05	0.000265	CcSEcCtD
Lenalidomide—Rash—Fluorouracil—urinary bladder cancer	6.04e-05	0.000265	CcSEcCtD
Lenalidomide—Dermatitis—Fluorouracil—urinary bladder cancer	6.04e-05	0.000265	CcSEcCtD
Lenalidomide—Pharyngitis—Doxorubicin—urinary bladder cancer	6.03e-05	0.000265	CcSEcCtD
Lenalidomide—Headache—Fluorouracil—urinary bladder cancer	6e-05	0.000263	CcSEcCtD
Lenalidomide—Urinary tract disorder—Doxorubicin—urinary bladder cancer	6e-05	0.000263	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—ESR1—urinary bladder cancer	5.99e-05	0.00161	CbGpPWpGaD
Lenalidomide—PTGS2—C-MYB transcription factor network—EP300—urinary bladder cancer	5.99e-05	0.00161	CbGpPWpGaD
Lenalidomide—Oedema peripheral—Doxorubicin—urinary bladder cancer	5.99e-05	0.000263	CcSEcCtD
Lenalidomide—Dysgeusia—Methotrexate—urinary bladder cancer	5.98e-05	0.000262	CcSEcCtD
Lenalidomide—Asthenia—Etoposide—urinary bladder cancer	5.97e-05	0.000262	CcSEcCtD
Lenalidomide—Connective tissue disorder—Doxorubicin—urinary bladder cancer	5.97e-05	0.000262	CcSEcCtD
Lenalidomide—Angiopathy—Epirubicin—urinary bladder cancer	5.96e-05	0.000261	CcSEcCtD
Lenalidomide—Urethral disorder—Doxorubicin—urinary bladder cancer	5.96e-05	0.000261	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	5.93e-05	0.00159	CbGpPWpGaD
Lenalidomide—Immune system disorder—Epirubicin—urinary bladder cancer	5.93e-05	0.00026	CcSEcCtD
Lenalidomide—Mediastinal disorder—Epirubicin—urinary bladder cancer	5.92e-05	0.00026	CcSEcCtD
Lenalidomide—Back pain—Methotrexate—urinary bladder cancer	5.91e-05	0.000259	CcSEcCtD
Lenalidomide—Chills—Epirubicin—urinary bladder cancer	5.89e-05	0.000258	CcSEcCtD
Lenalidomide—Pruritus—Etoposide—urinary bladder cancer	5.89e-05	0.000258	CcSEcCtD
Lenalidomide—Arrhythmia—Epirubicin—urinary bladder cancer	5.87e-05	0.000257	CcSEcCtD
Lenalidomide—Visual impairment—Doxorubicin—urinary bladder cancer	5.86e-05	0.000257	CcSEcCtD
Lenalidomide—Alopecia—Epirubicin—urinary bladder cancer	5.8e-05	0.000255	CcSEcCtD
Lenalidomide—Nausea—Gemcitabine—urinary bladder cancer	5.79e-05	0.000254	CcSEcCtD
Lenalidomide—Vomiting—Cisplatin—urinary bladder cancer	5.78e-05	0.000253	CcSEcCtD
Lenalidomide—Vision blurred—Methotrexate—urinary bladder cancer	5.76e-05	0.000253	CcSEcCtD
Lenalidomide—Mental disorder—Epirubicin—urinary bladder cancer	5.75e-05	0.000252	CcSEcCtD
Lenalidomide—Erythema multiforme—Doxorubicin—urinary bladder cancer	5.74e-05	0.000252	CcSEcCtD
Lenalidomide—Rash—Cisplatin—urinary bladder cancer	5.73e-05	0.000251	CcSEcCtD
Lenalidomide—Dermatitis—Cisplatin—urinary bladder cancer	5.72e-05	0.000251	CcSEcCtD
Lenalidomide—Erythema—Epirubicin—urinary bladder cancer	5.72e-05	0.000251	CcSEcCtD
Lenalidomide—Malnutrition—Epirubicin—urinary bladder cancer	5.72e-05	0.000251	CcSEcCtD
Lenalidomide—Diarrhoea—Etoposide—urinary bladder cancer	5.69e-05	0.00025	CcSEcCtD
Lenalidomide—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—urinary bladder cancer	5.69e-05	0.00153	CbGpPWpGaD
Lenalidomide—Nausea—Fluorouracil—urinary bladder cancer	5.69e-05	0.00025	CcSEcCtD
Lenalidomide—Eye disorder—Doxorubicin—urinary bladder cancer	5.68e-05	0.000249	CcSEcCtD
Lenalidomide—Ill-defined disorder—Methotrexate—urinary bladder cancer	5.67e-05	0.000249	CcSEcCtD
Lenalidomide—Tinnitus—Doxorubicin—urinary bladder cancer	5.67e-05	0.000248	CcSEcCtD
Lenalidomide—Anaemia—Methotrexate—urinary bladder cancer	5.65e-05	0.000248	CcSEcCtD
Lenalidomide—Flushing—Doxorubicin—urinary bladder cancer	5.64e-05	0.000247	CcSEcCtD
Lenalidomide—Cardiac disorder—Doxorubicin—urinary bladder cancer	5.64e-05	0.000247	CcSEcCtD
Lenalidomide—Flatulence—Epirubicin—urinary bladder cancer	5.63e-05	0.000247	CcSEcCtD
Lenalidomide—Tension—Epirubicin—urinary bladder cancer	5.61e-05	0.000246	CcSEcCtD
Lenalidomide—Dysgeusia—Epirubicin—urinary bladder cancer	5.6e-05	0.000246	CcSEcCtD
Lenalidomide—Nervousness—Epirubicin—urinary bladder cancer	5.55e-05	0.000244	CcSEcCtD
Lenalidomide—Back pain—Epirubicin—urinary bladder cancer	5.53e-05	0.000243	CcSEcCtD
Lenalidomide—Angiopathy—Doxorubicin—urinary bladder cancer	5.51e-05	0.000242	CcSEcCtD
Lenalidomide—Malaise—Methotrexate—urinary bladder cancer	5.51e-05	0.000242	CcSEcCtD
Lenalidomide—Dizziness—Etoposide—urinary bladder cancer	5.5e-05	0.000241	CcSEcCtD
Lenalidomide—Muscle spasms—Epirubicin—urinary bladder cancer	5.5e-05	0.000241	CcSEcCtD
Lenalidomide—Immune system disorder—Doxorubicin—urinary bladder cancer	5.49e-05	0.000241	CcSEcCtD
Lenalidomide—Vertigo—Methotrexate—urinary bladder cancer	5.49e-05	0.000241	CcSEcCtD
Lenalidomide—Mediastinal disorder—Doxorubicin—urinary bladder cancer	5.48e-05	0.00024	CcSEcCtD
Lenalidomide—Leukopenia—Methotrexate—urinary bladder cancer	5.47e-05	0.00024	CcSEcCtD
Lenalidomide—Chills—Doxorubicin—urinary bladder cancer	5.45e-05	0.000239	CcSEcCtD
Lenalidomide—PTGS2—Disease—GSTO2—urinary bladder cancer	5.43e-05	0.00146	CbGpPWpGaD
Lenalidomide—Arrhythmia—Doxorubicin—urinary bladder cancer	5.43e-05	0.000238	CcSEcCtD
Lenalidomide—Nausea—Cisplatin—urinary bladder cancer	5.4e-05	0.000237	CcSEcCtD
Lenalidomide—Vision blurred—Epirubicin—urinary bladder cancer	5.39e-05	0.000236	CcSEcCtD
Lenalidomide—Alopecia—Doxorubicin—urinary bladder cancer	5.37e-05	0.000236	CcSEcCtD
Lenalidomide—Cough—Methotrexate—urinary bladder cancer	5.33e-05	0.000234	CcSEcCtD
Lenalidomide—Mental disorder—Doxorubicin—urinary bladder cancer	5.32e-05	0.000233	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—CXCL8—urinary bladder cancer	5.32e-05	0.00143	CbGpPWpGaD
Lenalidomide—Ill-defined disorder—Epirubicin—urinary bladder cancer	5.3e-05	0.000233	CcSEcCtD
Lenalidomide—Vomiting—Etoposide—urinary bladder cancer	5.29e-05	0.000232	CcSEcCtD
Lenalidomide—Malnutrition—Doxorubicin—urinary bladder cancer	5.29e-05	0.000232	CcSEcCtD
Lenalidomide—Erythema—Doxorubicin—urinary bladder cancer	5.29e-05	0.000232	CcSEcCtD
Lenalidomide—Anaemia—Epirubicin—urinary bladder cancer	5.28e-05	0.000232	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—CREBBP—urinary bladder cancer	5.25e-05	0.00141	CbGpPWpGaD
Lenalidomide—Agitation—Epirubicin—urinary bladder cancer	5.25e-05	0.00023	CcSEcCtD
Lenalidomide—Rash—Etoposide—urinary bladder cancer	5.25e-05	0.00023	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	5.24e-05	0.00141	CbGpPWpGaD
Lenalidomide—Dermatitis—Etoposide—urinary bladder cancer	5.24e-05	0.00023	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	5.22e-05	0.0014	CbGpPWpGaD
Lenalidomide—PTGS2—C-MYB transcription factor network—MYC—urinary bladder cancer	5.22e-05	0.0014	CbGpPWpGaD
Lenalidomide—Headache—Etoposide—urinary bladder cancer	5.21e-05	0.000229	CcSEcCtD
Lenalidomide—Flatulence—Doxorubicin—urinary bladder cancer	5.21e-05	0.000229	CcSEcCtD
Lenalidomide—Myalgia—Methotrexate—urinary bladder cancer	5.2e-05	0.000228	CcSEcCtD
Lenalidomide—Chest pain—Methotrexate—urinary bladder cancer	5.2e-05	0.000228	CcSEcCtD
Lenalidomide—Arthralgia—Methotrexate—urinary bladder cancer	5.2e-05	0.000228	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	5.2e-05	0.00139	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—CXCL8—urinary bladder cancer	5.2e-05	0.00139	CbGpPWpGaD
Lenalidomide—Tension—Doxorubicin—urinary bladder cancer	5.19e-05	0.000228	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—IGF1—urinary bladder cancer	5.19e-05	0.00139	CbGpPWpGaD
Lenalidomide—Dysgeusia—Doxorubicin—urinary bladder cancer	5.18e-05	0.000227	CcSEcCtD
Lenalidomide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	5.16e-05	0.000227	CcSEcCtD
Lenalidomide—Malaise—Epirubicin—urinary bladder cancer	5.16e-05	0.000226	CcSEcCtD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—EP300—urinary bladder cancer	5.15e-05	0.00138	CbGpPWpGaD
Lenalidomide—Discomfort—Methotrexate—urinary bladder cancer	5.14e-05	0.000225	CcSEcCtD
Lenalidomide—Nervousness—Doxorubicin—urinary bladder cancer	5.14e-05	0.000225	CcSEcCtD
Lenalidomide—Vertigo—Epirubicin—urinary bladder cancer	5.14e-05	0.000225	CcSEcCtD
Lenalidomide—Syncope—Epirubicin—urinary bladder cancer	5.13e-05	0.000225	CcSEcCtD
Lenalidomide—Leukopenia—Epirubicin—urinary bladder cancer	5.12e-05	0.000224	CcSEcCtD
Lenalidomide—Back pain—Doxorubicin—urinary bladder cancer	5.12e-05	0.000224	CcSEcCtD
Lenalidomide—Muscle spasms—Doxorubicin—urinary bladder cancer	5.09e-05	0.000223	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—IL2—urinary bladder cancer	5.09e-05	0.00136	CbGpPWpGaD
Lenalidomide—Palpitations—Epirubicin—urinary bladder cancer	5.05e-05	0.000222	CcSEcCtD
Lenalidomide—Confusional state—Methotrexate—urinary bladder cancer	5.03e-05	0.00022	CcSEcCtD
Lenalidomide—Loss of consciousness—Epirubicin—urinary bladder cancer	5.02e-05	0.00022	CcSEcCtD
Lenalidomide—Cough—Epirubicin—urinary bladder cancer	4.99e-05	0.000219	CcSEcCtD
Lenalidomide—Vision blurred—Doxorubicin—urinary bladder cancer	4.98e-05	0.000219	CcSEcCtD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	4.98e-05	0.00133	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—IL2—urinary bladder cancer	4.97e-05	0.00133	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—CCND1—urinary bladder cancer	4.96e-05	0.00133	CbGpPWpGaD
Lenalidomide—Infection—Methotrexate—urinary bladder cancer	4.95e-05	0.000217	CcSEcCtD
Lenalidomide—Nausea—Etoposide—urinary bladder cancer	4.94e-05	0.000217	CcSEcCtD
Lenalidomide—Hypertension—Epirubicin—urinary bladder cancer	4.94e-05	0.000216	CcSEcCtD
Lenalidomide—Ill-defined disorder—Doxorubicin—urinary bladder cancer	4.91e-05	0.000215	CcSEcCtD
Lenalidomide—Nervous system disorder—Methotrexate—urinary bladder cancer	4.89e-05	0.000214	CcSEcCtD
Lenalidomide—Anaemia—Doxorubicin—urinary bladder cancer	4.89e-05	0.000214	CcSEcCtD
Lenalidomide—Thrombocytopenia—Methotrexate—urinary bladder cancer	4.88e-05	0.000214	CcSEcCtD
Lenalidomide—Chest pain—Epirubicin—urinary bladder cancer	4.87e-05	0.000213	CcSEcCtD
Lenalidomide—Arthralgia—Epirubicin—urinary bladder cancer	4.87e-05	0.000213	CcSEcCtD
Lenalidomide—Myalgia—Epirubicin—urinary bladder cancer	4.87e-05	0.000213	CcSEcCtD
Lenalidomide—Agitation—Doxorubicin—urinary bladder cancer	4.86e-05	0.000213	CcSEcCtD
Lenalidomide—Anxiety—Epirubicin—urinary bladder cancer	4.85e-05	0.000213	CcSEcCtD
Lenalidomide—Skin disorder—Methotrexate—urinary bladder cancer	4.84e-05	0.000212	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CCNE1—urinary bladder cancer	4.83e-05	0.0013	CbGpPWpGaD
Lenalidomide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	4.83e-05	0.000212	CcSEcCtD
Lenalidomide—PTGS2—C-MYB transcription factor network—KRAS—urinary bladder cancer	4.82e-05	0.00129	CbGpPWpGaD
Lenalidomide—Hyperhidrosis—Methotrexate—urinary bladder cancer	4.82e-05	0.000211	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—MMP9—urinary bladder cancer	4.81e-05	0.00129	CbGpPWpGaD
Lenalidomide—Discomfort—Epirubicin—urinary bladder cancer	4.81e-05	0.000211	CcSEcCtD
Lenalidomide—PTGS2—Metabolism—GSTZ1—urinary bladder cancer	4.8e-05	0.00129	CbGpPWpGaD
Lenalidomide—Malaise—Doxorubicin—urinary bladder cancer	4.77e-05	0.000209	CcSEcCtD
Lenalidomide—Dry mouth—Epirubicin—urinary bladder cancer	4.76e-05	0.000209	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—RHOA—urinary bladder cancer	4.75e-05	0.00127	CbGpPWpGaD
Lenalidomide—Vertigo—Doxorubicin—urinary bladder cancer	4.75e-05	0.000208	CcSEcCtD
Lenalidomide—Anorexia—Methotrexate—urinary bladder cancer	4.75e-05	0.000208	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—urinary bladder cancer	4.75e-05	0.00127	CbGpPWpGaD
Lenalidomide—Syncope—Doxorubicin—urinary bladder cancer	4.74e-05	0.000208	CcSEcCtD
Lenalidomide—Leukopenia—Doxorubicin—urinary bladder cancer	4.73e-05	0.000208	CcSEcCtD
Lenalidomide—Confusional state—Epirubicin—urinary bladder cancer	4.7e-05	0.000206	CcSEcCtD
Lenalidomide—PTGS2—Selenium Micronutrient Network—TNF—urinary bladder cancer	4.68e-05	0.00126	CbGpPWpGaD
Lenalidomide—Palpitations—Doxorubicin—urinary bladder cancer	4.67e-05	0.000205	CcSEcCtD
Lenalidomide—Oedema—Epirubicin—urinary bladder cancer	4.67e-05	0.000205	CcSEcCtD
Lenalidomide—Hypotension—Methotrexate—urinary bladder cancer	4.66e-05	0.000204	CcSEcCtD
Lenalidomide—Loss of consciousness—Doxorubicin—urinary bladder cancer	4.65e-05	0.000204	CcSEcCtD
Lenalidomide—Infection—Epirubicin—urinary bladder cancer	4.63e-05	0.000203	CcSEcCtD
Lenalidomide—Cough—Doxorubicin—urinary bladder cancer	4.62e-05	0.000202	CcSEcCtD
Lenalidomide—Shock—Epirubicin—urinary bladder cancer	4.59e-05	0.000201	CcSEcCtD
Lenalidomide—Nervous system disorder—Epirubicin—urinary bladder cancer	4.58e-05	0.000201	CcSEcCtD
Lenalidomide—Thrombocytopenia—Epirubicin—urinary bladder cancer	4.57e-05	0.0002	CcSEcCtD
Lenalidomide—Hypertension—Doxorubicin—urinary bladder cancer	4.57e-05	0.0002	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	4.56e-05	0.00122	CbGpPWpGaD
Lenalidomide—Tachycardia—Epirubicin—urinary bladder cancer	4.55e-05	0.0002	CcSEcCtD
Lenalidomide—PTGS2—Metabolism—GSTO2—urinary bladder cancer	4.55e-05	0.00122	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—NAT1—urinary bladder cancer	4.55e-05	0.00122	CbGpPWpGaD
Lenalidomide—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	4.54e-05	0.000199	CcSEcCtD
Lenalidomide—Skin disorder—Epirubicin—urinary bladder cancer	4.53e-05	0.000199	CcSEcCtD
Lenalidomide—Hyperhidrosis—Epirubicin—urinary bladder cancer	4.51e-05	0.000198	CcSEcCtD
Lenalidomide—Insomnia—Methotrexate—urinary bladder cancer	4.51e-05	0.000198	CcSEcCtD
Lenalidomide—Myalgia—Doxorubicin—urinary bladder cancer	4.5e-05	0.000198	CcSEcCtD
Lenalidomide—Chest pain—Doxorubicin—urinary bladder cancer	4.5e-05	0.000198	CcSEcCtD
Lenalidomide—Arthralgia—Doxorubicin—urinary bladder cancer	4.5e-05	0.000198	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	4.5e-05	0.00121	CbGpPWpGaD
Lenalidomide—Anxiety—Doxorubicin—urinary bladder cancer	4.49e-05	0.000197	CcSEcCtD
Lenalidomide—Paraesthesia—Methotrexate—urinary bladder cancer	4.48e-05	0.000196	CcSEcCtD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	4.47e-05	0.0012	CbGpPWpGaD
Lenalidomide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	4.47e-05	0.000196	CcSEcCtD
Lenalidomide—Discomfort—Doxorubicin—urinary bladder cancer	4.45e-05	0.000195	CcSEcCtD
Lenalidomide—Anorexia—Epirubicin—urinary bladder cancer	4.45e-05	0.000195	CcSEcCtD
Lenalidomide—Dyspnoea—Methotrexate—urinary bladder cancer	4.44e-05	0.000195	CcSEcCtD
Lenalidomide—Somnolence—Methotrexate—urinary bladder cancer	4.43e-05	0.000194	CcSEcCtD
Lenalidomide—Dry mouth—Doxorubicin—urinary bladder cancer	4.4e-05	0.000193	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—ERBB2—urinary bladder cancer	4.4e-05	0.00118	CbGpPWpGaD
Lenalidomide—Dyspepsia—Methotrexate—urinary bladder cancer	4.39e-05	0.000192	CcSEcCtD
Lenalidomide—Hypotension—Epirubicin—urinary bladder cancer	4.36e-05	0.000191	CcSEcCtD
Lenalidomide—Confusional state—Doxorubicin—urinary bladder cancer	4.35e-05	0.000191	CcSEcCtD
Lenalidomide—Decreased appetite—Methotrexate—urinary bladder cancer	4.33e-05	0.00019	CcSEcCtD
Lenalidomide—Oedema—Doxorubicin—urinary bladder cancer	4.32e-05	0.000189	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	4.3e-05	0.000189	CcSEcCtD
Lenalidomide—Fatigue—Methotrexate—urinary bladder cancer	4.3e-05	0.000189	CcSEcCtD
Lenalidomide—Infection—Doxorubicin—urinary bladder cancer	4.29e-05	0.000188	CcSEcCtD
Lenalidomide—Pain—Methotrexate—urinary bladder cancer	4.26e-05	0.000187	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	4.25e-05	0.000186	CcSEcCtD
Lenalidomide—Shock—Doxorubicin—urinary bladder cancer	4.25e-05	0.000186	CcSEcCtD
Lenalidomide—Nervous system disorder—Doxorubicin—urinary bladder cancer	4.23e-05	0.000186	CcSEcCtD
Lenalidomide—Thrombocytopenia—Doxorubicin—urinary bladder cancer	4.23e-05	0.000185	CcSEcCtD
Lenalidomide—PTGS2—Disease—SLC19A1—urinary bladder cancer	4.22e-05	0.00113	CbGpPWpGaD
Lenalidomide—Insomnia—Epirubicin—urinary bladder cancer	4.22e-05	0.000185	CcSEcCtD
Lenalidomide—Tachycardia—Doxorubicin—urinary bladder cancer	4.21e-05	0.000185	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	4.21e-05	0.00113	CbGpPWpGaD
Lenalidomide—Skin disorder—Doxorubicin—urinary bladder cancer	4.19e-05	0.000184	CcSEcCtD
Lenalidomide—Paraesthesia—Epirubicin—urinary bladder cancer	4.19e-05	0.000184	CcSEcCtD
Lenalidomide—Hyperhidrosis—Doxorubicin—urinary bladder cancer	4.17e-05	0.000183	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—CXCL8—urinary bladder cancer	4.17e-05	0.00112	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—UGT2B7—urinary bladder cancer	4.16e-05	0.00112	CbGpPWpGaD
Lenalidomide—Dyspnoea—Epirubicin—urinary bladder cancer	4.16e-05	0.000182	CcSEcCtD
Lenalidomide—Somnolence—Epirubicin—urinary bladder cancer	4.15e-05	0.000182	CcSEcCtD
Lenalidomide—PTGS2—Disease—PRSS3—urinary bladder cancer	4.12e-05	0.0011	CbGpPWpGaD
Lenalidomide—Anorexia—Doxorubicin—urinary bladder cancer	4.11e-05	0.00018	CcSEcCtD
Lenalidomide—Feeling abnormal—Methotrexate—urinary bladder cancer	4.11e-05	0.00018	CcSEcCtD
Lenalidomide—Dyspepsia—Epirubicin—urinary bladder cancer	4.11e-05	0.00018	CcSEcCtD
Lenalidomide—PTGS2—C-MYB transcription factor network—HRAS—urinary bladder cancer	4.1e-05	0.0011	CbGpPWpGaD
Lenalidomide—Gastrointestinal pain—Methotrexate—urinary bladder cancer	4.08e-05	0.000179	CcSEcCtD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	4.06e-05	0.00109	CbGpPWpGaD
Lenalidomide—Decreased appetite—Epirubicin—urinary bladder cancer	4.06e-05	0.000178	CcSEcCtD
Lenalidomide—Hypotension—Doxorubicin—urinary bladder cancer	4.03e-05	0.000177	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	4.03e-05	0.000177	CcSEcCtD
Lenalidomide—Fatigue—Epirubicin—urinary bladder cancer	4.02e-05	0.000176	CcSEcCtD
Lenalidomide—Constipation—Epirubicin—urinary bladder cancer	3.99e-05	0.000175	CcSEcCtD
Lenalidomide—Pain—Epirubicin—urinary bladder cancer	3.99e-05	0.000175	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—IL2—urinary bladder cancer	3.99e-05	0.00107	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—MYC—urinary bladder cancer	3.98e-05	0.00107	CbGpPWpGaD
Lenalidomide—Urticaria—Methotrexate—urinary bladder cancer	3.96e-05	0.000174	CcSEcCtD
Lenalidomide—Body temperature increased—Methotrexate—urinary bladder cancer	3.94e-05	0.000173	CcSEcCtD
Lenalidomide—Abdominal pain—Methotrexate—urinary bladder cancer	3.94e-05	0.000173	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	3.93e-05	0.000173	CcSEcCtD
Lenalidomide—PTGS2—Disease—HDAC4—urinary bladder cancer	3.93e-05	0.00105	CbGpPWpGaD
Lenalidomide—Insomnia—Doxorubicin—urinary bladder cancer	3.9e-05	0.000171	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—EGFR—urinary bladder cancer	3.89e-05	0.00104	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CCND1—urinary bladder cancer	3.89e-05	0.00104	CbGpPWpGaD
Lenalidomide—Paraesthesia—Doxorubicin—urinary bladder cancer	3.88e-05	0.00017	CcSEcCtD
Lenalidomide—Dyspnoea—Doxorubicin—urinary bladder cancer	3.85e-05	0.000169	CcSEcCtD
Lenalidomide—Feeling abnormal—Epirubicin—urinary bladder cancer	3.84e-05	0.000169	CcSEcCtD
Lenalidomide—Somnolence—Doxorubicin—urinary bladder cancer	3.84e-05	0.000168	CcSEcCtD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	3.82e-05	0.00102	CbGpPWpGaD
Lenalidomide—Gastrointestinal pain—Epirubicin—urinary bladder cancer	3.82e-05	0.000167	CcSEcCtD
Lenalidomide—Dyspepsia—Doxorubicin—urinary bladder cancer	3.8e-05	0.000167	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—MMP9—urinary bladder cancer	3.77e-05	0.00101	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CDKN1A—urinary bladder cancer	3.76e-05	0.00101	CbGpPWpGaD
Lenalidomide—Decreased appetite—Doxorubicin—urinary bladder cancer	3.75e-05	0.000165	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—PTEN—urinary bladder cancer	3.75e-05	0.00101	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—CYP4B1—urinary bladder cancer	3.75e-05	0.001	CbGpPWpGaD
Lenalidomide—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	3.73e-05	0.000163	CcSEcCtD
Lenalidomide—Fatigue—Doxorubicin—urinary bladder cancer	3.72e-05	0.000163	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	3.72e-05	0.000997	CbGpPWpGaD
Lenalidomide—Urticaria—Epirubicin—urinary bladder cancer	3.71e-05	0.000163	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—TNF—urinary bladder cancer	3.7e-05	0.000993	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	3.7e-05	0.000992	CbGpPWpGaD
Lenalidomide—Pain—Doxorubicin—urinary bladder cancer	3.69e-05	0.000162	CcSEcCtD
Lenalidomide—Constipation—Doxorubicin—urinary bladder cancer	3.69e-05	0.000162	CcSEcCtD
Lenalidomide—Body temperature increased—Epirubicin—urinary bladder cancer	3.69e-05	0.000162	CcSEcCtD
Lenalidomide—Abdominal pain—Epirubicin—urinary bladder cancer	3.69e-05	0.000162	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	3.69e-05	0.000988	CbGpPWpGaD
Lenalidomide—Hypersensitivity—Methotrexate—urinary bladder cancer	3.67e-05	0.000161	CcSEcCtD
Lenalidomide—ABCB1—Allograft Rejection—TNF—urinary bladder cancer	3.62e-05	0.00097	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—EP300—urinary bladder cancer	3.58e-05	0.000959	CbGpPWpGaD
Lenalidomide—Asthenia—Methotrexate—urinary bladder cancer	3.58e-05	0.000157	CcSEcCtD
Lenalidomide—Feeling abnormal—Doxorubicin—urinary bladder cancer	3.56e-05	0.000156	CcSEcCtD
Lenalidomide—PTGS2—Metabolism—SLC19A1—urinary bladder cancer	3.54e-05	0.000948	CbGpPWpGaD
Lenalidomide—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	3.53e-05	0.000155	CcSEcCtD
Lenalidomide—Pruritus—Methotrexate—urinary bladder cancer	3.53e-05	0.000155	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—SRC—urinary bladder cancer	3.48e-05	0.000933	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PRSS3—urinary bladder cancer	3.45e-05	0.000924	CbGpPWpGaD
Lenalidomide—Hypersensitivity—Epirubicin—urinary bladder cancer	3.44e-05	0.000151	CcSEcCtD
Lenalidomide—Urticaria—Doxorubicin—urinary bladder cancer	3.43e-05	0.00015	CcSEcCtD
Lenalidomide—Abdominal pain—Doxorubicin—urinary bladder cancer	3.41e-05	0.00015	CcSEcCtD
Lenalidomide—Body temperature increased—Doxorubicin—urinary bladder cancer	3.41e-05	0.00015	CcSEcCtD
Lenalidomide—Diarrhoea—Methotrexate—urinary bladder cancer	3.41e-05	0.00015	CcSEcCtD
Lenalidomide—ABCB1—Metabolism—GSTZ1—urinary bladder cancer	3.4e-05	0.000912	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	3.37e-05	0.000904	CbGpPWpGaD
Lenalidomide—Asthenia—Epirubicin—urinary bladder cancer	3.35e-05	0.000147	CcSEcCtD
Lenalidomide—Pruritus—Epirubicin—urinary bladder cancer	3.3e-05	0.000145	CcSEcCtD
Lenalidomide—Dizziness—Methotrexate—urinary bladder cancer	3.3e-05	0.000145	CcSEcCtD
Lenalidomide—PTGS2—Spinal Cord Injury—TP53—urinary bladder cancer	3.27e-05	0.000875	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	3.26e-05	0.000875	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	3.25e-05	0.000873	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	3.23e-05	0.000866	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—GSTO2—urinary bladder cancer	3.22e-05	0.000865	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—NAT1—urinary bladder cancer	3.22e-05	0.000865	CbGpPWpGaD
Lenalidomide—Diarrhoea—Epirubicin—urinary bladder cancer	3.19e-05	0.00014	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	3.19e-05	0.000855	CbGpPWpGaD
Lenalidomide—Hypersensitivity—Doxorubicin—urinary bladder cancer	3.18e-05	0.000139	CcSEcCtD
Lenalidomide—Vomiting—Methotrexate—urinary bladder cancer	3.17e-05	0.000139	CcSEcCtD
Lenalidomide—Rash—Methotrexate—urinary bladder cancer	3.14e-05	0.000138	CcSEcCtD
Lenalidomide—Dermatitis—Methotrexate—urinary bladder cancer	3.14e-05	0.000138	CcSEcCtD
Lenalidomide—Headache—Methotrexate—urinary bladder cancer	3.12e-05	0.000137	CcSEcCtD
Lenalidomide—PTGS2—Disease—LIG1—urinary bladder cancer	3.12e-05	0.000836	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—MYC—urinary bladder cancer	3.12e-05	0.000836	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	3.1e-05	0.000832	CbGpPWpGaD
Lenalidomide—Asthenia—Doxorubicin—urinary bladder cancer	3.1e-05	0.000136	CcSEcCtD
Lenalidomide—Dizziness—Epirubicin—urinary bladder cancer	3.09e-05	0.000135	CcSEcCtD
Lenalidomide—Pruritus—Doxorubicin—urinary bladder cancer	3.05e-05	0.000134	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—EGFR—urinary bladder cancer	3.05e-05	0.000818	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	3.02e-05	0.000809	CbGpPWpGaD
Lenalidomide—Vomiting—Epirubicin—urinary bladder cancer	2.97e-05	0.00013	CcSEcCtD
Lenalidomide—Nausea—Methotrexate—urinary bladder cancer	2.96e-05	0.00013	CcSEcCtD
Lenalidomide—Diarrhoea—Doxorubicin—urinary bladder cancer	2.95e-05	0.00013	CcSEcCtD
Lenalidomide—ABCB1—Metabolism—UGT2B7—urinary bladder cancer	2.95e-05	0.000791	CbGpPWpGaD
Lenalidomide—Rash—Epirubicin—urinary bladder cancer	2.94e-05	0.000129	CcSEcCtD
Lenalidomide—Dermatitis—Epirubicin—urinary bladder cancer	2.94e-05	0.000129	CcSEcCtD
Lenalidomide—Headache—Epirubicin—urinary bladder cancer	2.92e-05	0.000128	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—KRAS—urinary bladder cancer	2.88e-05	0.000772	CbGpPWpGaD
Lenalidomide—Dizziness—Doxorubicin—urinary bladder cancer	2.85e-05	0.000125	CcSEcCtD
Lenalidomide—Nausea—Epirubicin—urinary bladder cancer	2.77e-05	0.000122	CcSEcCtD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	2.76e-05	0.000741	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—TYMP—urinary bladder cancer	2.76e-05	0.000739	CbGpPWpGaD
Lenalidomide—Vomiting—Doxorubicin—urinary bladder cancer	2.74e-05	0.00012	CcSEcCtD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	2.74e-05	0.000735	CbGpPWpGaD
Lenalidomide—Rash—Doxorubicin—urinary bladder cancer	2.72e-05	0.000119	CcSEcCtD
Lenalidomide—Dermatitis—Doxorubicin—urinary bladder cancer	2.72e-05	0.000119	CcSEcCtD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	2.71e-05	0.000725	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	2.7e-05	0.000725	CbGpPWpGaD
Lenalidomide—Headache—Doxorubicin—urinary bladder cancer	2.7e-05	0.000119	CcSEcCtD
Lenalidomide—ABCB1—Metabolism—CYP4B1—urinary bladder cancer	2.66e-05	0.000712	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	2.65e-05	0.00071	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	2.65e-05	0.000709	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	2.65e-05	0.000709	CbGpPWpGaD
Lenalidomide—Nausea—Doxorubicin—urinary bladder cancer	2.56e-05	0.000112	CcSEcCtD
Lenalidomide—CDH5—Signaling Pathways—TP53—urinary bladder cancer	2.56e-05	0.000686	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	2.52e-05	0.000675	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—SLC19A1—urinary bladder cancer	2.51e-05	0.000672	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	2.5e-05	0.00067	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—NAT2—urinary bladder cancer	2.49e-05	0.000668	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—HRAS—urinary bladder cancer	2.45e-05	0.000656	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PRSS3—urinary bladder cancer	2.44e-05	0.000655	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	2.39e-05	0.000641	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—ENO2—urinary bladder cancer	2.38e-05	0.000638	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	2.31e-05	0.00062	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	2.31e-05	0.000619	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—RBX1—urinary bladder cancer	2.26e-05	0.000605	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	2.22e-05	0.000595	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	2.2e-05	0.00059	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—RRM2—urinary bladder cancer	2.15e-05	0.000577	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	2.14e-05	0.000574	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—JAG1—urinary bladder cancer	2.02e-05	0.000541	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—ENO2—urinary bladder cancer	1.99e-05	0.000534	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—HPGDS—urinary bladder cancer	1.99e-05	0.000534	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.98e-05	0.000531	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—TYMP—urinary bladder cancer	1.95e-05	0.000524	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—GSTT1—urinary bladder cancer	1.93e-05	0.000518	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	1.92e-05	0.000514	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.9e-05	0.00051	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	1.88e-05	0.000503	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	1.79e-05	0.000479	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	1.77e-05	0.000475	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—NAT2—urinary bladder cancer	1.77e-05	0.000474	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—NQO1—urinary bladder cancer	1.61e-05	0.000431	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	1.57e-05	0.000422	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—RRM2—urinary bladder cancer	1.53e-05	0.000409	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—NCOR1—urinary bladder cancer	1.47e-05	0.000394	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—HPGDS—urinary bladder cancer	1.41e-05	0.000379	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—ENO2—urinary bladder cancer	1.41e-05	0.000379	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—ERCC2—urinary bladder cancer	1.38e-05	0.000371	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—GSTT1—urinary bladder cancer	1.37e-05	0.000367	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.36e-05	0.000364	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—GSTP1—urinary bladder cancer	1.34e-05	0.000359	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—MTHFR—urinary bladder cancer	1.3e-05	0.000348	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.3e-05	0.000347	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—TERT—urinary bladder cancer	1.3e-05	0.000347	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	1.28e-05	0.000344	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—TYMS—urinary bladder cancer	1.25e-05	0.000334	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—NCOR1—urinary bladder cancer	1.23e-05	0.00033	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—GSTM1—urinary bladder cancer	1.23e-05	0.00033	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—FGFR3—urinary bladder cancer	1.19e-05	0.000319	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—GPX1—urinary bladder cancer	1.18e-05	0.000316	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—ERCC2—urinary bladder cancer	1.16e-05	0.00031	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—NQO1—urinary bladder cancer	1.14e-05	0.000305	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—MTHFR—urinary bladder cancer	1.09e-05	0.000292	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CREBBP—urinary bladder cancer	1.01e-05	0.000271	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—GSTP1—urinary bladder cancer	9.5e-06	0.000255	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—RHOA—urinary bladder cancer	9.16e-06	0.000245	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—TYMS—urinary bladder cancer	8.83e-06	0.000237	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PPARG—urinary bladder cancer	8.82e-06	0.000237	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—NCOR1—urinary bladder cancer	8.73e-06	0.000234	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—GSTM1—urinary bladder cancer	8.73e-06	0.000234	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—CREBBP—urinary bladder cancer	8.48e-06	0.000227	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—ERBB2—urinary bladder cancer	8.48e-06	0.000227	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—GPX1—urinary bladder cancer	8.36e-06	0.000224	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—ERCC2—urinary bladder cancer	8.21e-06	0.00022	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—MTHFR—urinary bladder cancer	7.71e-06	0.000207	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CDKN1A—urinary bladder cancer	7.24e-06	0.000194	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—PTEN—urinary bladder cancer	7.23e-06	0.000194	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—EP300—urinary bladder cancer	6.89e-06	0.000185	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—SRC—urinary bladder cancer	6.7e-06	0.00018	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PPARG—urinary bladder cancer	6.25e-06	0.000168	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PTEN—urinary bladder cancer	6.05e-06	0.000162	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—CREBBP—urinary bladder cancer	6.01e-06	0.000161	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—MYC—urinary bladder cancer	6.01e-06	0.000161	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—EGFR—urinary bladder cancer	5.87e-06	0.000157	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—EP300—urinary bladder cancer	5.77e-06	0.000155	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—KRAS—urinary bladder cancer	5.55e-06	0.000149	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PTGS2—urinary bladder cancer	4.92e-06	0.000132	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—HRAS—urinary bladder cancer	4.72e-06	0.000126	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PTEN—urinary bladder cancer	4.29e-06	0.000115	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—EP300—urinary bladder cancer	4.09e-06	0.00011	CbGpPWpGaD
